# A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

> **NCT00687271** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 334 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** MK-6213
- **DRUG:** Atorvastatin calcium
- **DRUG:** Placebo for MK-6312 160 mg
- **DRUG:** Placebo for Atorvastatin 20 mg

## Key facts

- **NCT ID:** NCT00687271
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-14
- **Primary completion:** 2009-01-08
- **Final completion:** 2009-01-08
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687271, "A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00687271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*